Literature DB >> 3142674

A hypercalcemic nude rat model that completely mimics human syndrome of humoral hypercalcemia of malignancy.

K Ikeda1, T Matsumoto, S Fukumoto, K Kurokawa, Y Ueyama, K Fujishige, N Tamaoki, T Saito, K Ohtake, E Ogata.   

Abstract

Tumors causing humoral hypercalcemia of malignancy (HHM) were implanted to athymic nude rats. In one of these rat models transplanted with uterine cancer (UCC), a complete reproduction of human HHM syndrome was achieved: hypercalcemia, hypophosphatemia with increased urinary phosphate and cyclic AMP excretion, and suppressed serum 1,25-dihydroxy-vitamin D (1,25(OH)2D) level. In another hypercalcemic nude rat model implanted with oral cavity cancer (OCC), all the features were similar except for markedly elevated serum 1,25(OH)2D. Hypercalcemia disappeared by surgical removal of the tumors in both models, confirming the humoral mechanisms for causing these features. Furthermore, in UCC tumor-bearing rats, hypophosphatemia, increased renal phosphate excretion, and reduced serum 1,25(OH)2D concentration were already present when these rats were only marginally hypercalcemic. These results raise the possibility that the changes in renal tubular phosphate handling and vitamin D metabolism in HHM are not secondary to hypercalcemia but are due to direct effects of the humoral factor(s) that cause this syndrome. Extracts of both tumors exhibited stimulation of cyclic AMP production in osteoblastlike cells, UMR 106, which could be almost completely inhibited by parathyroid hormone (PTH) antagonist, human PTH(3-34). By comparing the nature and characteristics of humoral factor(s) from UCC and OCC models, mechanisms responsible for causing these abnormalities can be explored. Thus, these nude rat models can be useful for elucidating the underlying mechanism of the development of HHM.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142674     DOI: 10.1007/bf02555154

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  23 in total

1.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.

Authors:  A F Stewart; R Horst; L J Deftos; E C Cadman; R Lang; A E Broadus
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245

2.  The hypercalcemic rat Leydig cell tumor--a model of the humoral hypercalcemia of malignancy.

Authors:  D A Sica; R R Martodam; J Aronow; G R Mundy
Journal:  Calcif Tissue Int       Date:  1983-05       Impact factor: 4.333

3.  The hypercalcaemic syndrome in rats bearing the Walker carcinosarcoma 256.

Authors:  H Minne; F Raue; S Bellwinkel; R Ziegler
Journal:  Acta Endocrinol (Copenh)       Date:  1975-03

4.  Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy.

Authors:  K J Ibbotson; S M D'Souza; K W Ng; C K Osborne; M Niall; T J Martin; G R Mundy
Journal:  Science       Date:  1983-09-23       Impact factor: 47.728

5.  Human renal carcinoma cells produce hypercalcemia in the nude mouse and a novel protein recognized by parathyroid hormone receptors.

Authors:  G J Strewler; R D Williams; R A Nissenson
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

6.  Identification of adenylate cyclase-stimulating activity and cytochemical glucose-6-phosphate dehydrogenase-stimulating activity in extracts of tumors from patients with humoral hypercalcemia of malignancy.

Authors:  A F Stewart; K L Insogna; D Goltzman; A E Broadus
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

7.  Biochemical and histomorphometric characterization of a rat model for humoral hypercalcemia of malignancy.

Authors:  K L Insogna; A F Stewart; A M Vignery; E C Weir; P A Namnum; R E Baron; J M Kirkwood; L M Deftos; A E Broadus
Journal:  Endocrinology       Date:  1984-03       Impact factor: 4.736

8.  A model for malignancy-associated humoral hypercalcemia.

Authors:  E C Abramson; L J Kukla; D H Shevrin; T E Lad; W P McGuire; S C Kukreja
Journal:  Calcif Tissue Int       Date:  1984-09       Impact factor: 4.333

9.  Effect of dibutyryl adenosine 3',5'-monophosphate administration on plasma concentrations of 1,25-dihydroxyvitamin D in pseudohypoparathyroidism type I.

Authors:  K Yamaoka; Y Seino; M Ishida; T Ishii; T Shimotsuji; Y Tanaka; H Kurose; S Matsuda; K Satomura; H Yabuuchi
Journal:  J Clin Endocrinol Metab       Date:  1981-11       Impact factor: 5.958

10.  Squamous carcinoma model of humoral hypercalcemia of malignancy.

Authors:  P J Gkonos; T Hayes; W Burtis; R Jacoby; J McGuire; R Baron; A F Stewart
Journal:  Endocrinology       Date:  1984-12       Impact factor: 4.736

View more
  2 in total

Review 1.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

Review 2.  Animal Models of Cancer-Associated Hypercalcemia.

Authors:  Nicole A Kohart; Said M Elshafae; Justin T Breitbach; Thomas J Rosol
Journal:  Vet Sci       Date:  2017-04-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.